First Trust Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $126M | Buy |
959,217
+472,408
| +97% | +$62.7M | 0.09% | 279 |
|
|
2025
Q4 | $69M | Buy |
486,809
+123,696
| +34% | +$17.9M | 0.05% | 438 |
|
|
2025
Q3 | $51M | Sell |
363,113
-60,358
| -14% | -$8.18M | 0.04% | 559 |
|
|
2025
Q2 | $53.2M | Sell |
423,471
-169,884
| -29% | -$19.5M | 0.04% | 516 |
|
|
2025
Q1 | $65.6M | Buy |
593,355
+198,703
| +50% | +$25.2M | 0.06% | 433 |
|
|
2024
Q4 | $53.9M | Sell |
394,652
-149,669
| -27% | -$18.5M | 0.05% | 480 |
|
|
2024
Q3 | $62.7M | Buy |
544,321
+110,784
| +26% | +$15.2M | 0.06% | 404 |
|
|
2024
Q2 | $59.7M | Sell |
433,537
-93,045
| -18% | -$12.8M | 0.06% | 366 |
|
|
2024
Q1 | $72.6M | Sell |
526,582
-64,143
| -11% | -$8.76M | 0.07% | 325 |
|
|
2023
Q4 | $77.8M | Buy |
590,725
+127,085
| +27% | +$14.6M | 0.08% | 297 |
|
|
2023
Q3 | $52.2M | Sell |
463,640
-67,244
| -13% | -$7.08M | 0.06% | 407 |
|
|
2023
Q2 | $50.1M | Sell |
530,884
-143,132
| -21% | -$14M | 0.06% | 447 |
|
|
2023
Q1 | $68.2M | Buy |
674,016
+298
| +0% | +$31K | 0.08% | 364 |
|
|
2022
Q4 | $80.5M | Sell |
673,718
-91,049
| -12% | -$10.7M | 0.1% | 308 |
|
|
2022
Q3 | $81.2M | Buy |
764,767
+193,015
| +34% | +$19.6M | 0.11% | 266 |
|
|
2022
Q2 | $55.7M | Sell |
571,752
-68,707
| -11% | -$6.34M | 0.07% | 422 |
|
|
2022
Q1 | $60M | Buy |
640,459
+43,447
| +7% | +$3.68M | 0.06% | 466 |
|
|
2021
Q4 | $50.8M | Sell |
597,012
-81,261
| -12% | -$7.47M | 0.05% | 495 |
|
|
2021
Q3 | $65.1M | Buy |
678,273
+30,718
| +5% | +$2.9M | 0.07% | 370 |
|
|
2021
Q2 | $63M | Sell |
647,555
-6,451
| -1% | -$618K | 0.07% | 389 |
|
|
2021
Q1 | $63.6M | Buy |
654,006
+15,949
| +2% | +$1.67M | 0.08% | 360 |
|
|
2020
Q4 | $61.2M | Sell |
638,057
-206,232
| -24% | -$19.9M | 0.08% | 339 |
|
|
2020
Q3 | $81.2M | Sell |
844,289
-12,747
| -1% | -$1.47M | 0.13% | 189 |
|
|
2020
Q2 | $105M | Sell |
857,036
-81,342
| -9% | -$8.99M | 0.18% | 133 |
|
|
2020
Q1 | $81.2M | Buy |
938,378
+296,167
| +46% | +$29M | 0.18% | 136 |
|
|
2019
Q4 | $69M | Sell |
642,211
-78,397
| -11% | -$8.21M | 0.12% | 235 |
|
|
2019
Q3 | $64.9M | Sell |
720,608
-557,092
| -44% | -$52M | 0.12% | 214 |
|
|
2019
Q2 | $108M | Buy |
1,277,700
+194,643
| +18% | +$16M | 0.2% | 110 |
|
|
2019
Q1 | $95.4M | Sell |
1,083,057
-216,398
| -17% | -$18.1M | 0.19% | 132 |
|
|
2018
Q4 | $92.8M | Buy |
1,299,455
+278,598
| +27% | +$26.7M | 0.22% | 85 |
|
|
2018
Q3 | $126M | Buy |
1,020,857
+41,186
| +4% | +$4.67M | 0.23% | 77 |
|
|
2018
Q2 | $96.2M | Buy |
979,671
+52,200
| +6% | +$4.67M | 0.2% | 99 |
|
|
2018
Q1 | $76.9M | Buy |
927,471
+74,636
| +9% | +$6.3M | 0.18% | 110 |
|
|
2017
Q4 | $66.2M | Buy |
852,835
+70,150
| +9% | +$4.78M | 0.16% | 125 |
|
|
2017
Q3 | $48M | Buy |
782,685
+176,136
| +29% | +$9.29M | 0.12% | 175 |
|
|
2017
Q2 | $27.9M | Sell |
606,549
-48,733
| -7% | -$2.36M | 0.07% | 339 |
|
|
2017
Q1 | $28.4M | Sell |
655,282
-22,928
| -3% | -$982K | 0.08% | 316 |
|
|
2016
Q4 | $26.2M | Buy |
678,210
+92,588
| +16% | +$4.19M | 0.08% | 336 |
|
|
2016
Q3 | $29.7M | Sell |
585,622
-31,415
| -5% | -$1.56M | 0.09% | 281 |
|
|
2016
Q2 | $28M | Sell |
617,037
-21,250
| -3% | -$978K | 0.09% | 280 |
|
|
2016
Q1 | $25.2M | Buy |
+638,287
| New | +$25.3M | 0.08% | 314 |
|
Other funds holding NBIX
VPM
VCM
First Trust Advisors's NBIX Position: Q1 2026 in Review
First Trust Advisors increased its Neurocrine Biosciences (NBIX) stake by 97% in Q1 2026, buying an estimated $62.7M and bringing the position to 959,217 shares worth $126M. The position accounts for 0.09% of the portfolio, ranked #279.
First Trust Advisors first reported a position in NBIX in Q1 2016 and has held it in 41 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- First Trust Advisors held 959,217 shares of Neurocrine Biosciences worth $126M as of Q1 2026.
- First Trust Advisors bought 472,408 Neurocrine Biosciences shares in Q1 2026, an estimated $62.7M.
- Neurocrine Biosciences made up 0.09% of First Trust Advisors's portfolio in Q1 2026, its #279 holding.
- First Trust Advisors first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 41 quarters since.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.